Released May 13, 2019, after the close
10-Q filed May 14, 2019, 44 days after period end · 0001493152-19-007099
Q1 2019 · 10-Q
Revenue$4.83M$4.83M −16.1% vs Q1 2018−18.4% vs Q4 2018
Net Income-$313.00K-$313.00K N/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$0.11-$0.11 N/M vs Q1 2018no prior Q4 2018 on file
Operating Income-$217,000N/M
Operating Cash Flow$780,000N/M
Free Cash Flowderived$739,000N/M
Margins · derived
Operating margin-4.5%+0.9 pt vs Q1 2018
Net margin-6.5%+0.6 pt vs Q1 2018
What the release said
The release
Same quarter
| Metric | Q1 2019 | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|---|
| Revenue | $4.83M | $5.76M | $5.23M | $5.48M |
| Net Income | -$313.00K | -$409.00K | -$90.00K | -$1.04M |
| EPS Diluted | -$0.11 | -$0.16 | -$0.04 | -$0.57 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR